rAd-Rv2299c
Candidate Overview
rAd-Rv2299c is a chimpanzee adenovirus-vectored vaccine expressing Rv2299c. Constructed using pRSK17 shuttle plasmid, packaged in HEK293A cells, and purified by cesium chloride density centrifugation. Formulated for intranasal inhalation at 1×10⁸ PFU/50 μL PBS. The platform exhibits low human seroprevalence with trained immunity induction in DCs. No exogenous adjuvants.
Sponsor / Lead Developer: Shanghai Public Health Clinical Center, Fudan University
Primary Indication: Prevention of Mtb infection or sustained infection
Other Indication(s): Prevention of TB disease
Target Population(s): Adolescents and Adults
Target Route of Administration: Aerosol
Immune tissue localization: Lung
Immunological responses: T-cell
Preclinical Animal Models: Mouse
Intended to elicit trained immunity: Yes
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | T-cell | |
| T-cell phenotype | CD4 CD8 | |
| T-cell functional profile | IFN-γ TNF-α IL-17 | |
| Preferential immune tissue localization | Lung | |
| Trained immunity | Yes | |